Transplantation, Autologous: Transplantation of an individual's own tissue from one site to another site.Hematopoietic Stem Cell Transplantation: Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.Transplantation, Homologous: Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Blood Transfusion, Autologous: Reinfusion of blood or blood products derived from the patient's own circulation. (Dorland, 27th ed)Transplantation Conditioning: Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.Bone Marrow Transplantation: The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.Graft vs Host Disease: The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.Stem Cell Transplantation: The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.Peripheral Blood Stem Cell Transplantation: Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.Cyclophosphamide: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.T-Lymphocytes: Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.Whole-Body Irradiation: Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.Remission Induction: Therapeutic act or process that initiates a response to a complete or partial remission level.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.Recurrence: The return of a sign, symptom, or disease after a remission.Bone Marrow Purging: Techniques for the removal of subpopulations of cells (usually residual tumor cells) from the bone marrow ex vivo before it is infused. The purging is achieved by a variety of agents including pharmacologic agents, biophysical agents (laser photoirradiation or radioisotopes) and immunologic agents. Bone marrow purging is used in both autologous and allogeneic BONE MARROW TRANSPLANTATION.Myeloablative Agonists: Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION.Busulfan: An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.Cytotoxicity, Immunologic: The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.T-Lymphocytes, Cytotoxic: Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.Lymphocyte Activation: Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)Lymphocyte Culture Test, Mixed: Measure of histocompatibility at the HL-A locus. Peripheral blood lymphocytes from two individuals are mixed together in tissue culture for several days. Lymphocytes from incompatible individuals will stimulate each other to proliferate significantly (measured by tritiated thymidine uptake) whereas those from compatible individuals will not. In the one-way MLC test, the lymphocytes from one of the individuals are inactivated (usually by treatment with MITOMYCIN or radiation) thereby allowing only the untreated remaining population of cells to proliferate in response to foreign histocompatibility antigens.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Salvage Therapy: A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.Disease-Free Survival: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)Hodgkin Disease: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.Survival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.Hematopoietic Stem Cell Mobilization: The release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of leukapheresis, prior to stem cell transplantation. Hematopoietic growth factors or chemotherapeutic agents often are used to stimulate the mobilization.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Immunotherapy, Adoptive: Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)Antigens, Neoplasm: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.Etoposide: A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.Immunotherapy: Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.Graft Survival: The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.Antigens, CD34: Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Cytarabine: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)Hematologic Diseases: Disorders of the blood and blood forming tissues.Cancer Vaccines: Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).Tissue Donors: Individuals supplying living tissue, organs, cells, blood or blood components for transfer or transplantation to histocompatible recipients.Dendritic Cells: Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION).Cells, Cultured: Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.HLA Antigens: Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.Hematopoietic Stem Cells: Progenitor cells from which all blood cells derive.Histocompatibility Testing: Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed)Cell Transplantation: Transference of cells within an individual, between individuals of the same species, or between individuals of different species.Bone Transplantation: The grafting of bone from a donor site to a recipient site.Histocompatibility: The degree of antigenic similarity between the tissues of different individuals, which determines the acceptance or rejection of allografts.Graft vs Leukemia Effect: Immunological rejection of leukemia cells following bone marrow transplantation.Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)Platelet-Rich Plasma: A preparation consisting of PLATELETS concentrated in a limited volume of PLASMA. This is used in various surgical tissue regeneration procedures where the GROWTH FACTORS in the platelets enhance wound healing and regeneration.Flow Cytometry: Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.Platelet Transfusion: The transfer of blood platelets from a donor to a recipient or reinfusion to the donor.Graft vs Tumor Effect: Immunological rejection of tumor tissue/cells following bone marrow transplantation.Prospective Studies: Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.Acute Disease: Disease having a short and relatively severe course.Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.Killer Cells, Natural: Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Chimerism: The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with MOSAICISM in which the different cell populations are derived from a single individual.Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Interleukin-2: A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.Autografts: Transplant comprised of an individual's own tissue, transferred from one part of the body to another.Vidarabine: A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.Hepatic Veno-Occlusive Disease: Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.Transplantation Chimera: An organism that, as a result of transplantation of donor tissue or cells, consists of two or more cell lines descended from at least two zygotes. This state may result in the induction of donor-specific TRANSPLANTATION TOLERANCE.CD4-Positive T-Lymphocytes: A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.Feasibility Studies: Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.
Younger individuals, if at high risk for dying from CLL, may consider allogeneic hematopoietic stem cell transplantation (HSCT ... Autologous stem cell transplantation, using the recipient's own cells, is not curative. ... Source: Modified from WHO Blue Book on Tumour of Hematopoietic and Lymphoid Tissues. 2001, p. 2001.) CS1 maint: Uses authors ...
The trial was to test the efficacy and safety of autologous (using the patient's own cells) hematopoietic stem cell ... transplantation (HSCT) after genetic modification to deliver a super-therapeutic (over-expressing) ARSA enzyme to the nervous ... Gene therapy with an autologous stem cell transplant - Italian researchers at the San Raffaele Telethon Institute tested a ... 2013). "Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy". Science. 341 (6148): 1233158. ...
... who have relapsed or progressed after autologous hematopoietic stem cell transplantation (auto-HSCT) and post-transplantation ...
Autologous HSCT requires the extraction (apheresis) of haematopoietic stem cells (HSC) from the patient and storage of the ... Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ... These advantages have established autologous HSCT as one of the standard second-line treatments for such diseases as lymphoma. ... Post-HSCT oral cancer may have more aggressive behavior with poorer prognosis, when compared to oral cancer in non-HSCT ...
For this reason, allogeneic HSCT leads to a higher cure rate than autologous transplantation for several cancer types, although ... Allogeneic hematopoietic stem cell transplantation ("bone marrow transplantation" from a genetically non-identical donor) can ... This is known as autologous stem cell transplantation. Targeted therapy, which first became available in the late 1990s, has ... Damodar, S; Terunuma H; Abraham S (October 2006). "Autologous Immune Enhancement Therapy (AIET) for a Case of Acute Myeloid ...
Autologous hematopoietic stem cell transplantation (HSCT) is based on the assumption that autoimmune diseases like systemic ... van Laar JM, Farge Sont JK, ET AL., for the EBMT/EULAR Scleroderma Study Group (June 25, 2014). "Autologous Hematopoietic Stem ... The authors concluded that HSCT could be effective, if limited to patients who were healthy enough to survive HSCT itself. ... "Autologous Hematopoietic Stem Cell Therapy in Severe Systemic Sclerosis: Ready for Clinical Practice?". JAMA. 311 (24): 2485- ...
Autologous[edit]. Autologous HSCT requires the extraction (apheresis) of haematopoietic stem cells (HSC) from the patient and ... Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ... These advantages have established autologous HSCT as one of the standard second-line treatments for such diseases as lymphoma.[ ... Patients after HSCT are at a higher risk for oral carcinoma. Post-HSCT oral cancer may have more aggressive behavior with ...
There may be a higher risk of infection with cord blood compared with traditional HSCT, as cord blood is slower in generating ... The EGE concluded that "[t]he legitimacy of commercial cord blood banks for autologous use should be questioned as they sell a ... Cord Blood Hematopoietic Cell Transplantation". In Appelbaum, Frederick R.; Forman, Stephen J.; Negrin, Robert S.; Blume, Karl ... 2008). "Autologous umbilical cord blood infusion for type 1 diabetes". Exp. Hematol. 36 (6): 710-715. doi:10.1016/j.exphem. ...
Hematopoietic stem cell transplantation (HSCT) is the transplantation of blood stem cells derived from the bone marrow (that is ... 1999). "Autologous haematopoietic stem cell transplants for autoimmune disease--feasibility and transplant-related mortality. ... Hematopoietic stem cell transplantation remains a risky procedure with many possible complications; it has traditionally been ... With the availability of the stem cell growth factors GM-CSF and G-CSF, most hematopoietic stem cell transplantation procedures ...
There are three types of HSCT: syngeneic, autologous, and allogeneic transplants. Syngeneic transplantations occur between ... Hwang WYK (2004). "Haematopoietic graft engineering". Annals, Academy of Medicine, Singapore. 33: 551-558. Hwang WYK, Ong SY ( ... Autologous transplantations use the HSCs obtained directly from the patient and hence do not cause any complications of tissue ... To lower the risks of transplant, which include graft rejection and Graft-Versus-Host Disease (GVHD), allogeneic HSCT must ...
1999). «Autologous haematopoietic stem cell transplants for autoimmune disease--feasibility and transplant-related mortality. ... Hematopoetisk stamcelletransplantasjon (HSCT) er transplantasjonen av multipotente hematopoetiske stamceller, vanlegvis henta ... Denne artikkelen bygger på «Hematopoietic stem cell transplantation» frå Wikipedia på engelsk, den 8. januar 2015. ...
Hematopoietic stem cell transplantation (HSCT) with high intensity conditioning protocol has been performed in a few cases with ... "Autologous haematopoietic stem cell transplantation for neurological diseases". J Neurol Neurosurg Psychiatry. 89 (2): 147-155 ... There is a limited but encouraging therapeutic experience of hematopoietic stem cell transplantation for SPS. ... "Autologous Stem Cell Transplantation for Stiff Person Syndrome". JAMA Neurology. 71 (10): 1296-9. doi:10.1001/jamaneurol. ...
HSCT) after long-term (,12) versus short-term (,12) months cryopreservation ... Retrospective analysis of outcome following autologous haematopoietic stem cell transplantation ( ... Retrospective analysis of outcome following autologous haematopoietic stem cell transplantation (HSCT) after long-term (>12) ... Retrospective analysis of outcome following autologous haematopoietic stem cell transplantation (HSCT) after long-term (>12) ...
Over the last two decades, autologous haematopoietic stem cell transplantation (auto-HSCT) has emerged as a promising treatment ... Herein, we review current experience of auto-HSCT for the treatment of CD as well as approaches that have been used to monitor ... Mechanistic studies have provided proof-of-concept that auto-HSCT can restore immunological tolerance in chronic autoimmunity ... Mechanistic studies have provided proof-of-concept that auto-HSCT can restore immunological tolerance in chronic autoimmunity ...
Abbreviation / Long Form : HSCT / hematopoietic allogeneic- (allo-) and autologous- (auto-) stem cell transplant. ... HSCT / hematopoietic allogeneic- (allo-) and autologous- (auto-) stem cell transplant (1 time). ... HSCT (,, Co-occurring Abbreviation) Long Form:. hematopoietic allogeneic- (allo-) and autologous- (auto-) stem cell transplant ...
Myeloablative autologous hematopoietic stem cell transplantation (HSCT) is a mainstay of therapy for relapsed intermediate- ... Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.. Wang ... Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL ... Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL ...
HSCT) has been used to treat patients with severe autoimmune and inflammatory diseases whose response to standard treatment ... The vast majority of patients have received autologous HSCT where an increasing evidence-base supports its use in a wide range ... Over the last 20 years, haematopoietic stem cell transplantation (HSCT) has been used to treat patients with severe autoimmune ... General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune ...
Myeloma Following Autologous Hematopoietic Stem Cell Transplant (auto-HSCT) REVLIMID is the first and only treatment approved ... following autologous hematopoietic stem cell transplantation (auto-HSCT) ... multiple myeloma as maintenance therapy following autologous hematopoietic stem cell transplant (auto-HSCT). The expanded ... "Autologous stem cell transplant after induction therapy is part of the continuum of care for transplant-eligible multiple ...
The competitive landscape in the global market for hematopoietic stem cell transplantation (HSCT) is characterized by the ... HSCT) Market has been segmented as follows:. By Transplant Type. Allogeneic. Family Related. Unrelated. Autologous. By Disease ... Browse the Hematopoietic Stem Cell Transplantation (HSCT) Market (Transplant Type - Allogeneic (Family Related and Unrelated) ... Hematopoietic Stem Cell Transplantation (HSCT) Market Research, Growth Opportunities, Key Players, Outlook and Forecasts Report ...
The study has two treatment arms; arm A: HSCT (hematopoietic stem cell transplantation) and arm B: alemtuzumab, a registered ... RCT Comparing Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab in MS (RAM-MS). The safety and scientific ... A randomized study regarding with statistical power to evaluate the clinical outcome of autologous HSCT compared to a standard ... Randomized Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab for Patients With Relapsing Remitting Multiple ...
HSCT) has been shown to be effective. However, it is associated with a high rate of procedure-related complications.{ref153}{ ... Autologous hematopoietic stem cell transplantation for systemic sclerosis. Curr Stem Cell Res Ther. 2011 Mar. 6(1):16-28. [ ... Hematopoietic stem cell transplantation (HSCT) has been shown to be effective. However, it is associated with a high rate of ... Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic ...
... in patients who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients will be enrolled prior ... Allogeneic Hematopoietic Stem Cell Biological: fecal microbiota transplantation (FMT) Other: No fecal microbiota ... Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of ... This is a randomized, open-label, controlled study designed to assess the efficacy of autologous fecal microbiota ...
Since autologous hematopoietic stem cell transplantation (HSCT) allows the usage of higher doses of chemotherapy, which results ... Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients. The safety ... The usage of high-dose chemotherapy with autologous HSCT, is one of the therapies that have been studied in the patients with ... Autologous HSCT allows higher chemotherapy doses, which results in higher tumor cells destruction. Since 1980, several phase II ...
Autologous and allogeneic haematopoietic stem cell transplantation (HSCT). Previously referred to as high‑dose therapy in the ...
United States Hematopoietic Stem Cell Transplantation (HSCT) Market 2017 (Allogeneic and Autologous) Leading Growth Drivers, ...
Advances in the Treatment of Scleroderma (SSc): Autologous Hematopoietic Stem Cell Transplant (HSCT). HSCT can be considered as ... Advances in the Treatment of Scleroderma (SSc): Autologous Hematopoietic Stem Cell Transplant (HSCT). Joelf posted a topic in ...
Younger individuals, if at high risk for dying from CLL, may consider allogeneic hematopoietic stem cell transplantation (HSCT ... Autologous stem cell transplantation, using the recipients own cells, is not curative. ... Source: Modified from WHO Blue Book on Tumour of Hematopoietic and Lymphoid Tissues. 2001, p. 2001.) CS1 maint: Uses authors ...
HSCT, haematopoietic stem cell transplantation. *IP, interstitial pneumonia. *mRSS, modified Rodnan skin score ... Results: Haematopoietic reconstitution was rapid and sustained. Toxicity due to the regimen included various infections such as ... Conclusions: These observations suggest that high dose CY with autologous PBSCT is feasible and may be effective in the ... A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease ...
New data supports the safety and efficacy of GSKs Shingrix in preventing shingles in autologous haematopoietic stem cell ... Hematopoietic stem cell transplantation (HSCT) in adults is most commonly performed as part of the treatment for blood cancer. ... About the ZOE-HSCT Study. ZOE-HSCT was a Phase III clinical study to evaluate the efficacy, safety and immunogenicity of a two- ... New data supports the safety and efficacy of GSKs Shingrix in preventing shingles in autologous haematopoietic stem cell ...
Here, we performed autologous hematopoietic stem cell transplantation (HSCT) in three Simian/Human Immunodeficiency Virus (SHIV ... with 37-53 days of ART before autologous HSCT, and interruption of ART after hematopoietic reconstitution, rather than ... Effect of autologous HSCT on CD4+ T-cells. Following transplantation and engraftment, we observed a rapid increase in the ... TiTLE HERE- - > Persistence of Virus Reservoirs in ART-Treated SHIV-Infected Rhesus Macaques after Autologous Hematopoietic ...
Stiff skin syndrome and myeloma successfully treated with autologous haematopoietic stem cell transplantation (HSCT). ... Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow ... Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of ...
Has received a previous allogeneic HSCT (Note: receipt of a previous autologous HSCT is acceptable). ... Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228- ... Is within 28 days post-HSCT at the time of enrollment.. *Females are not pregnant, not breastfeeding,and is not a woman of ... Has evidence of CMV viremia at any time from either signing of the ICF or the HSCT procedure, whichever is earlier, until the ...
HSCT) is considered an effective way to prevent relapse in adults with acute lymphoblastic leukemia (ALL). This study aimed to ... a All allogeneic HSCT. b Matched sibling donor HSCT. c Unrelated donor HSCT. d Mismatched related donor HSCT. e Autologous HSCT ... of autologous HSCT recipients compared with 17% between 2001 and 2003.. Table 2 Trends in the use of hematopoietic stem cell ... Acute lymphoblastic leukemia Allogeneic hematopoietic stem cell transplantation Autologous hematopoietic stem cell ...
Relapsed after prior autologous hematopoietic stem cell transplantation. (HSCT). - No current transformation of lymphoma (e.g ... No prior allogeneic HSCT. - No other immunotherapy during and for approximately 65 days after the last T-cell. infusion, unless ... Hematopoietic. - Absolute neutrophil count > 500/mm^3. Hepatic. - Bilirubin ≤ 1.5 times upper limit of normal (ULN)* (unless ... autologous cytotoxic T lymphocytes genetically modified to express a CD19-specific. chimeric immunoreceptor gene and HyTK ...
HSCT) - A Pilot Study Clinical Trial reports on BioPortfolio ... Probiotic Use in Children Undergoing Hematopoietic Stem Cell ... Autologous hematopoietic stem cell transplantation (Auto-HSCT) is an effective alternative to allogeneic HSCT for low-risk and ... Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment of malignant hematopoietic diseases. ... Allogeneic hematopoietic stem cell transplantation (allo-HSCT) appears to be an efficient tool to cure standard-risk acute ...
Some people with rapidly progressive scleroderma may be candidates for autologous hematopoietic stem cell transplantation (HSCT ... Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018;378(1):35-47. PMID: 29298160 ...
AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT) ... AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT) ...
  • Here, we performed autologous hematopoietic stem cell transplantation (HSCT) in three Simian/Human Immunodeficiency Virus (SHIV)-infected, antiretroviral therapy (ART)-treated rhesus macaques (RMs) using HSCs collected prior to infection and compared them to three SHIV-infected, ART-treated, untransplanted control animals to assess the effect of conditioning and autologous HSCT on viral persistence. (natap.org)
  • GVHD is a complication of HSCT in which immune cells from the donor cause inflammation and injury to tissues and organs of the HSCT recipient. (bioportfolio.com)
  • Have suspected Grade II to Grade IV aGVHD occurring after allo-HSCT and after any preventative GVHD treatment. (rush.edu)
  • Due to the obvious lack of genetic disparity between donor and recipient, the existence of autologous GVHD (AGVHD) has been a topic of controversy [ 2 - 5 ]. (termedia.pl)
  • Autologous HSCT using genetically corrected cells would avoid the risk of graft-versus-host disease (GVHD), but the genotoxicity of conditioning remains a substantial barrier to the development of this approach. (nih.gov)
  • Our analysis showed a continued trend toward increased allogeneic HSCT use for adults with ALL, which may be attributed to increasing availability of unrelated donors, wider use of RIC regimens, and improving efficacy of pretransplant therapy, including tyrosine kinase inhibitors for Ph-positive ALL. (springer.com)
  • More recently, two HIV-infected individuals have been described with prolonged (i.e., 3-8 months) suppression of viremia in absence of ART following allogeneic HSCT from donors homozygous for the wild type ccr5 allele , . (prolekare.cz)
  • Donors for allogeneic HSCT may come from the patient's family, or may be unrelated and provided by donor registries. (smw.ch)
  • If the treatment efficacy obtained by HSCT is better than the currently most efficacious standard, immunomodulatory treatment in randomized treatment trials, HSCT will likely be approved as a part of the standard treatment recommendations for a significant proportion of RRMS patients. (clinicaltrials.gov)
  • Patients will also be invited to consent to a longer term follow up study, which will collect data on the safety and efficacy of the HSCT procedure for at least a further four years after the main trial. (sheffield.ac.uk)
  • This article reviews the biology of stem cells, clinical efficacy of HSCT, transplantation procedures, and potential complications. (dovepress.com)
  • A randomized study regarding with statistical power to evaluate the clinical outcome of autologous HSCT compared to a standard immunomodulatory treatment in MS has not yet been published. (clinicaltrials.gov)
  • Clinical trials include 2 studies of REVLIMID as a maintenance therapy after an auto-HSCT. (revlimid.com)
  • Complete a Phase I/II clinical trial for X-linked Chronic Granulomatous disease (X-CGD) with Lentivirus transduced autologous CD34+ hematopoietic stem cells. (ca.gov)
  • No severe adverse effects were noted in our previous clinical application of UCMSCs in HSCT. (hindawi.com)
  • Dr Emma Gray, head of clinical trials at UK's MS Society, said: "Ongoing research suggests stem cell treatments such as HSCT could offer hope, and it's clear that, in the cases highlighted by Panorama, they've had a life-changing impact. (sbs.com.au)
  • Several clinical trials of HSCT for MS have been published. (mssociety.org.uk)
  • Compared with standard treatments for autoimmune diseases, HSCT is associated with greater short-term risks, including a risk of treatment-related mortality and long-term complications. (nih.gov)
  • The aim of this open-access position statement is to provide plainly worded guidance for patients and non-specialist clinicians considering HSCT for an autoimmune disease, especially when treatment abroad is being considered. (nih.gov)
  • The expanded indication makes REVLIMID the first and only treatment to receive FDA approval for maintenance use following auto-HSCT. (businesswire.com)
  • Data from recently published patient series indicate that HSCT may have a significantly higher treatment effect than currently registered RRMS immunomodulatory treatments. (clinicaltrials.gov)
  • This is a randomized study of autologous HSCT using a low intensity, non-ablative conditioning regimen with cyclophosphamide and ATG versus treatment with the currently presumed best available immunomodulatory medication (alemtuzumab) in RRMS patients with significant inflammatory disease activity in spite of ongoing immunomodulatory MS treatment. (clinicaltrials.gov)
  • Except for Sweden, HSCT is currently not registered as a part of standard MS treatment in the public health services of Europe. (clinicaltrials.gov)
  • Accordingly, the proposed study should provide a robust basis for future official decisions regarding the role of HSCT in RRMS treatment. (clinicaltrials.gov)
  • What is the role of HSCT in the treatment of scleroderma? (medscape.com)
  • In ASTIS during the first year, 13 events, including 8 treatment-related deaths, occurred in the HSCT group and 8 events with no treatment-related deaths occurred in the control group (16.5% vs. 10.4%, respectively). (medscape.com)
  • REVLIMID is the only multiple myeloma treatment FDA approved for maintenance therapy after an auto-HSCT. (revlimid.com)
  • Immunosuppressant therapy with drugs and dosages high enough to be severely myelosuppressive, followed by HSCT, had been tested previously in patients with advanced, progressive MS, for which there is currently no broadly effective treatment. (medpagetoday.com)
  • Adipose-derived stem cell-enriched lipografts produced aesthetically-acceptable results without the need for repeat treatment sessions, which are necessary with autologous fat transplantation. (cellmedicinesociety.org)
  • In the NHL trial, 90% (135/150 participants) in the plerixafor treatment cohort and 55% (82/148 participants) in the placebo cohort had an HSCT after mobilization. (unicare.com)
  • Haematopoietic refers to the type of stem cells used in the treatment, which are found in the bone marrow and blood and make new blood and immune cells. (msra.org.au)
  • Almost all people who had HSCT showed no signs of their condition getting worse a year after the treatment, and some experienced improvement. (mssociety.org.uk)
  • Initiate Adcetris treatment within 4-6 weeks post-auto-HSCT or upon recovery from auto-HSCT. (drugs.com)
  • Mechanistic studies have provided proof of concept that auto-HSCT can restore immunological tolerance in chronic autoimmunity via the eradication of pathological immune responses and a profound reconfiguration of the immune system. (frontiersin.org)
  • After pursuing the development of cellular therapies to treat immune disorders, Dr. Brenner shifted the focus of his research to bone marrow transplantation, or what is now called HSCT. (liebertpub.com)
  • The reduction in toxicity with RIC results in less morbidity and mortality, and has made allogeneic HSCT available to patients with comorbidities and to older patients (i.e., patients aged 60 to 70 years, the age group that has the highest prevalence of most haematopoietic malignancies). (smw.ch)
  • The global HSCT market is gaining significantly from the remarkable rise in the geriatric population and the escalating prevalence of non-communicable diseases across the world," says a TMR analyst. (sbwire.com)
  • Both the EFS rate and CIR were significantly better in the allo-HSCT group than in other groups. (sigmaaldrich.com)
  • The study team concluded that among adults who had undergone autologous HSCT, a 2-dose course of recombinant zoster vaccine significantly reduced the incidence of herpes zoster over a median follow-up of 21 months. (esmo.org)
  • However, trials have found that, while HSCT may be able to stabilise or improve disability in some people with MS, it may not be effective for all types of the condition. (sbs.com.au)
  • However, when ART was interrupted, a rapid rebound of plasma viremia was observed in two out of three transplanted RM indicating that the massive reset of the hematopoietic compartment was not sufficient to eliminate the total-body virus reservoir in the setting of short term ART. (prolekare.cz)
  • Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. (nih.gov)
  • RAM-MS is an international phase 3 trial comparing HSCT with alemtuzumab (Lemtrada), which is one of the most effective disease modifying therapies (DMTs) currently available. (mssociety.org.uk)